The Wall Street Journal: Novavax delays its COVID-19 vaccine timeline


Novavax Inc. has delayed plans to seek regulatory clearances for its COVID-19 vaccine, while shortages in raw materials are slowing the ramp-up of production of doses, the company said.

The delays may set back efforts to increase vaccinations in developing countries, which have been dealing with limited doses of currently available shots and are looking forward to Novavax’s.

Previously, Novavax

said it expected to complete requests for regulatory authorizations of its COVID-19 vaccine in the U.S., the U.K. and other European countries by the end of June. Now, the company said Monday it expects to complete those filings by the end of September.

Novavax said it also pushed back the timetable for when it expects to reach full production output of about 150 million doses a month, to the fourth quarter this year from a prior target of the third quarter.

An expanded version of this report appears on

Also popular on

Catholic schools are losing students at record rates, and hundreds are closing.

The breakout cities on the forefront of America’s economic recovery.

Earnings Results: Wynn to take online-gambling arm public with help of a SPAC

Previous article

The Moneyist: I bought my parents’ house at below-market rate as a favor — now my sister wants me to finance an extension to house our mother

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News